Core Insights - PALI-2108 is the first and only PDE4 inhibitor specifically designed to target the terminal ileum and colon for treating fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC), addressing significant unmet medical needs in these conditions [1] - The inflammatory bowel disease market in China is projected to approach $1 billion in total revenues by 2030, indicating a large and growing market opportunity [1] Company Developments - The China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, with a base patent term extending into 2045, subject to regulatory approval extensions [2] - The CEO of Palisade Bio emphasized the importance of strengthening the global intellectual property portfolio for PALI-2108, which supports the company's clinical and strategic objectives in one of the fastest-growing pharmaceutical markets [3] - Palisade Bio is currently conducting a Phase 1b/2a clinical trial for PALI-2108 aimed at treating FSCD and UC, with multiple near-term clinical milestones expected in the next 12-18 months [3] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, aiming to transform the treatment landscape through targeted approaches [4]

Core Viewpoint - AMTD Group Inc. and its subsidiary The Generation Essentials Group have successfully taken legal actions against Luxury Village LLC for intellectual property infringement, reinforcing their commitment to protecting their brands and trademarks [1][5]. Legal Actions and Outcomes - On July 25, 2025, AMTD secured a court order against Luxury Village LLC, mandating the cessation of prohibited operations and the relinquishment of domain names that wrongfully incorporated "lofficiel" [2]. - AMTD successfully transferred the domain names <lofficiel.au> and <lofficielfashionbook.hk> back to itself following legal proceedings [2]. - A significant victory was achieved by blocking Luxury Village LLC's bad faith application for the "L'OFFICIEL FASHION BOOK" trademark in Australia, with the Registrar of Trade Marks ruling against the application [3][4]. Intellectual Property Protection - The legal rulings emphasize AMTD's rights to intellectual property and highlight the bad faith actions of Luxury Village LLC in misleadingly suggesting an affiliation with AMTD [5]. - AMTD has taken down several infringing domain names, including <lofficiel.co>, <lofficiel.co.com>, and others, to protect its international profile and growth [6]. Caution to Partners and Public - The company warns partners and the public to avoid dealings with unauthorized entities that falsely present themselves as part of AMTD's network, such as L'Officiel Austria and others [7]. Company Overview - AMTD Group operates across various sectors, including media and entertainment, education and training, and premium assets and hospitality [8]. - AMTD IDEA Group serves as a diversified institution and digital solutions provider, connecting companies and investors with global markets [9]. - AMTD Digital Inc. offers a comprehensive digital solutions platform, focusing on digital media, content, marketing services, and hospitality [11]. - The Generation Essentials Group focuses on global strategies in multimedia, entertainment, and cultural affairs, comprising a diversified media and entertainment portfolio [12].

Core Viewpoint - GoPro, Inc. announced that an Administrative Law Judge (ALJ) of the International Trade Commission (ITC) found that Insta360 violated federal law by importing and selling products that infringe on GoPro's intellectual property related to its HERO camera design [1]. Group 1: Legal Findings - The ALJ's findings confirm that Insta360 infringed on GoPro's patent covering the HERO camera design (US Patent D789,435) and validated multiple patent claims related to GoPro's HyperSmooth video stabilization technology (US Patents 10,574,894 and 10,958,840) [2]. - GoPro plans to address other outstanding issues in its infringement case against Insta360 with the full ITC, which is expected to issue a Final Determination on all claims by November 10, 2025 [3]. Group 2: Intellectual Property and Innovation - The litigation process has enhanced GoPro's intellectual property portfolio, highlighting the company's history of innovation, which has resulted in over 1,500 US patents [3]. - GoPro's CEO, Nicholas Woodman, emphasized the company's commitment to protecting its intellectual property while welcoming fair competition that drives innovation [4].

Core Insights - Ethical Web AI has successfully onboarded its first AI Vault SaaS client via the AWS Marketplace, marking a significant milestone in its 2025 strategic roadmap [1][2] - The AI Vault product addresses key challenges in generative AI adoption, including transparency, security, and regulatory compliance, and is backed by multiple patents [2][4] - The company aims to secure five enterprise customers through AWS Marketplace by the end of the month and targets capturing 10% of the enterprise generative AI market within three years [3] Product and Innovation Strategy - Ethical Web AI's product development is driven by a strategy that emphasizes patent protection, ensuring that all software developed can be legally protected [4][5] - The company has a growing portfolio of intellectual property that underpins its product strategy, with each product linked to specific enforceable claims [5][7] - The AI Vault is specifically designed for the 27% of companies that currently prohibit generative AI due to privacy and security concerns, particularly in sectors like finance [8] Patent Portfolio - The company holds a foundational patent (US Patent 10,977,387) valued at $4.7 billion, which supports its Open-Source Platform and includes features like anonymous search [6] - Additional patent applications are in progress, enhancing capabilities such as contextual enveloping and sensitive data processing in generative AI [9] Future Outlook - Ethical Web AI aims to become cash generative within twelve months and is considering an uplist to a superior exchange like NASDAQ [11] - The company is exploring acquisition opportunities, leveraging its strong IP position and growing commercial traction [11][12] - The focus remains on scaling responsibly while delivering value to customers and shareholders [12]

Core Insights - Hoth Therapeutics has secured Japan Country Patent No. 7677628 for its HT-KIT platform, providing exclusive protection until August 27, 2039 [1][6] - The patent covers a novel method using splice-switching oligonucleotides (SSOs) to target KIT gene expression in mast cells, which are involved in various conditions including chronic hives and rare cancers [2][6] - The CEO of Hoth Therapeutics emphasized the strategic importance of this patent in the Asian pharmaceutical market and the potential for licensing opportunities [3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies aimed at improving patient quality of life [4] - The company is actively seeking global partners for co-development and commercialization of its therapeutic platforms, particularly in Asia [3] Patent Details - The granted patent is specifically applicable to mast cell-driven inflammatory and oncologic conditions, positioning the company for orphan indications and expedited regulatory pathways [6]

Core Viewpoint - Treace Medical Concepts, Inc. has filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. for patent infringement related to its Lapiplasty® 3D Bunion Correction® technologies, seeking injunctive relief and damages [1]. Group 1: Company Overview - Treace Medical Concepts is a medical technology company focused on advancing surgical treatment for bunions and midfoot deformities, with an estimated 67 million Americans affected by bunions, of which 1.1 million are annual surgical candidates [3]. - The company has developed and patented the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in three planes and stabilizing the affected joint [3]. - Treace's patent portfolio includes 80 granted U.S. patents and 26 granted patents worldwide, along with over 150 pending patent applications, highlighting its commitment to innovation and intellectual property protection [2]. Group 2: Legal Action - The lawsuit filed by Treace aims to protect its significant investments in research and technology, emphasizing the importance of enforcing intellectual property rights to foster continued innovation [2]. - The legal action is seen as a necessary step to safeguard the company's pioneering position in the surgical treatment of bunions [2].

Core Insights - Supernus Pharmaceuticals, Inc. has received Paragraph IV Notice Letters from third parties regarding Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules in 100, 150, and 200 mg doses [1][2] - The company is reviewing these Notice Letters and plans to enforce its intellectual property rights related to its product Qelbree, which is protected by six U.S. patents with expiration dates ranging from September 2029 to April 2035 [2] Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for central nervous system (CNS) diseases [3] - The company's neuroscience portfolio includes treatments for ADHD, dyskinesia in Parkinson's disease, epilepsy, migraine, and other CNS disorders, with ongoing development of new candidates for epilepsy and depression [4]

Core Viewpoint - Scienture Holdings, Inc. has announced the FDA listing of two patents for its product Arbli, a novel oral liquid formulation of losartan, which is expected to enhance its market position and provide statutory exclusivity under the Hatch-Waxman Act [1][2][6]. Company Overview - Scienture Holdings, Inc. is a holding company focused on developing and distributing specialty pharmaceutical products that address unmet market needs [1][13]. - The company operates through its subsidiary, Scienture, LLC, which is dedicated to bringing unique specialty products to market [13]. Product Details - Arbli is the first FDA-approved ready-to-use oral liquid formulation of losartan, designed for patients over 6 years old, and is indicated for the treatment of hypertension and related conditions [3][4][8]. - The product is available in a 165 mL bottle with a peppermint flavor, has a shelf life of 18 months at room temperature, and does not require refrigeration [7]. Market Position - The patents for Arbli cover stable liquid formulations of losartan and methods of use, reinforcing Scienture's intellectual property position [2]. - Losartan is classified as an angiotensin receptor blocker (ARB) and is one of the most prescribed medications for hypertension, with annual sales of approximately $276 million and a prescription volume of 69 million in the U.S. market as of March 2025 [5]. Regulatory Milestone - The listing of Arbli in the FDA's Orange Book is considered a significant regulatory achievement for Scienture, validating its development efforts and enhancing its commercial pathway in the U.S. market [6][2].

Core Viewpoint - Cerence Inc. has filed a lawsuit against Microsoft and Nuance Communications for copyright infringement and breach of contract, focusing on its text-to-speech technology, which is crucial for its product offerings in automotive and other sectors [1][2][3]. Company Overview - Cerence Inc. is a global leader in AI-powered user experiences, particularly in the automotive and transportation industries, with over 500 million cars equipped with its technology [4]. - The company emphasizes its commitment to protecting its intellectual property rights and plans to defend its innovations vigorously [3][4]. Legal Context - The lawsuit aims to safeguard Cerence's significant investments in its intellectual property portfolio, particularly its text-to-speech technology, which is foundational to its operations [2][3]. - The action against Microsoft and Nuance is seen as necessary to uphold the company's culture of innovation and protect its market position as it expands beyond automotive applications [3].

As filed with the U.S. Securities and Exchange Commission on July 15, 2024. Registration No. 333-279771 Ontario, Canada 2834 Not Applicable (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDICUS PHARMA LTD. (Exact name of Registrant as specifie ...